Dr. Paul R. Billings M.D., Ph.D. joined the Board of Directors in August, 2015 and serves as a Consultant in Strategy, Alliances and Competitive Intelligence for IR2Dx. Dr. Billings has extensive expertise and health care experience in the areas of genomics, molecular medicine, personalized medicine and diagnostics. He’s a Board certified internist and clinical geneticist. He currently is CMO and Senior Vice President of Medical Affairs of Natera, a company focused on noninvasive prenatal genetic testing and screening. He has served on the Scientific Advisory Board of the Food and Drug Administration and the Genomic Medicine Advisory Committee at the Department of Veterans Affairs. Dr. Billings was the Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in the Silicon Valley. He was the former Chief Medical Officer of Life Technologies Inc. and the Genetic Sciences Division of ThermoFisher Scientific, both unique positions aimed at improving patient care using medically relevant genomic technologies in clinical settings. He has been a founder or chief executive officer of several companies involved in genetic and personalized diagnostic medicine, a director of others, and was senior vice president for corporate development at Laboratory Corporation of America Holdings (NYSE; LH).
Dr. Billings has had a distinguished career as a physician and researcher. He has held academic appointments at Harvard University, U.C. San Francisco, Stanford University and U.C. Berkeley, and has served as a physician at a number of leading medical centers. He is the author of nearly 200 publications and books on experimental and clinical medicine. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University.